Go back to News
NEWS
IAM Patent 1000 Annual Ranking
24 of October, 2024
Recognition in the Silver category of the IAM Patent 1000 awards
The Firm has been awarded ‘Silver’ in the Patent Litigation category according to the annual ranking of the IAM Patent 1000 directory.
In addition, Jesús Muñoz-Delgado stands out in the ‘Gold’ category as a ‘Global Leader’, for his specialisation in Life Sciences, and specifically in patent matters in the biotechnology sector. Recognised for his strategic advice, he is involved in pan-European disputes and handles complex patent litigation with great skill.
To be included in IAM Global Leaders, practitioners must be ranked in the Golden category of the IAM Patent 1000, the annual benchmark directory that highlights the top law firms and specialists in the world’s most relevant patent jurisdictions.
Press contact
Director of Business Development, Marketing and Communications
Director of Business Development, Marketing and Communications
More information about
Gómez-Acebo & Pombo
03 Feb, 2026 
PUBLICATION
26 Feb, 2026
Pharma & Healthcare No. 47
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
26 Feb, 2026 
PUBLICATION
29 Jan, 2026
On Call Protocol for the Alimentaria and Hostelco 2026 Trade Fairs
In preparation for the Alimentaria and Hostelco 2026 trade fairs, the Commercial Section of the Barcelona First Instance Court has approved a rapid response protocol to deal promptly with any potential conflicts relating to intellectual and industrial property rights (patents,trademarks, designs, and copyright), as well as trade secrets and unfair competition issues that may arise during these events.
29 Jan, 2026
PUBLICATION
27 Jan, 2026
Jurisdiction of national courts of States party to the Agreement on a Unified Patent Court in respect of actions relating to classic European patents during the transitional period
During the transitional period of the Agreement on a Unified Patent Court, national courts retain jurisdiction to hear cases concerning classic European patents, without the need for the proprietor to have exercised the opt-out option, i.e. without the need to have excluded the jurisdiction of the Unified Patent Court over such patents. However, the Venice Court ruling discussed here considers that national courts may only be used if the opt-out has been exercised, contradicting the provisions of Article 83 of the Agreement.
27 Jan, 2026
PUBLICATION
21 Jan, 2026
Incompatibility between practising a healthcare profession and having a pecuniary interest in the manufacture or sale of medicinal products or medical devices
Royal Legislative Decree 1/2015, of 24 July, approving the recast version of the Medicinal Products and Medical Devices (Guarantees and Rational Use) Act, prohibits healthcare professionals with prescribing powers from having a direct pecuniary interest in activities related to medicines. This prohibition does not extend to indirect interests, as distinguished in Article 4 of said legislative decree. Judgment no. 483/2025 of the High Court of Justice of the Basque Country concludes that mere membership of a group of companies does not entail incompatibility if each entity retains real autonomy.
21 Jan, 2026
PUBLICATION
15 Jan, 2026
Excessive extension of the Bolar clause in the 'pharmaceutical legislative package'
The Bolar clause allows studies and trials necessary to obtain marketing authorisations for medicinal products to be carried out without infringing patents. Its scope has grown during the passage of the pharmaceutical legislative package, incorporating more actors and more activities, to include participation in public tenders before the patent expires. This extension raises questions about compatibility with the TRIPS Agreement, which only allows limited exceptions to patent rights. Participation in tenders could be considered an offer to sell, thus violating the limits set by that agreement.
15 Jan, 2026
PUBLICATION
19 Dec, 2025
Requirements for lawful descriptive use of a third-party trade mark with reputation
In Judgment 1505/2025, the Supreme Court analyses the use of the term 'Donut' by a competitor that markets ring-shaped pastry under another trade mark. Although previous instances considered the use to be merely descriptive, the Supreme Court rejects this on the grounds that it is a reputed trade mark, which triggers enhanced protection. This protection requires avoiding any unfair use of the prestige or distinctive character of the trade mark. The court concludes that the use made was not fair and may involve parasitism and dilution.
19 Dec, 2025
PUBLICATION
18 Dec, 2025
Prepared for the 2026 Mobile World Congress?
The protocol, agreed jointly by the Courts of Barcelona and Alicante, provides for priority handling of applications for pre-trial examination and fact-finding orders, as well as applications for interim measures —with or without a hearing— in matters relating to patents and technological innovations, industrial designs, trademarks and copyright, as well as antitrust, unfair competition and unlawful advertising, when linked to products or presentation, display, promotion, offering or sale activities connected to MWC 2026.
18 Dec, 2025
PUBLICATION
09 Dec, 2025
Pharma & Healthcare No. 46
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
09 Dec, 2025
PUBLICATION
07 Nov, 2025
Domain name infringement of a subsequently registered trade mark
An interesting ruling has recently been handed down in relation to a case in which a domain name holder turned to the courts after losing in the ICANN (Internet Corporation for Assigned Names and Numbers) procedure, specifically Supreme Court (Civil Division) Judgment no. 1341/2025 of 30 September (ECLI:ES:TS:2025:4206).
07 Nov, 2025